MRM Health Strengthens Board with Michel Detheux as Chairman and Hans-Jürgen Wörle as Independent Director as MH002 Advances Through Phase 2b
The appointments position MRM Health for its next key clinical, partnering and financing milestones
MRM Health, a clinical-stage biotech developing microbiome-based therapies for immune-mediated diseases, today announced the appointment of two experienced industry leaders to its Board of Directors as the Company enters a pivotal phase of growth. With its lead program, MH002, in Phase 2b clinical development, recent FDA Fast Track designation and a €55 million Series B financing, MRM Health is strengthening its Board to support the Company through its next clinical, strategic and financing milestones. Michel Detheux, PhD, has been appointed Chairman of the Board of Directors, taking over from Werner Cautreels. Prof. Dr. med. Hans-Jürgen Wörle joins the Board as an Independent Director.
“MRM Health is entering a pivotal phase, with MH002 advancing into Phase 2b clinical development and significant momentum across the business. The appointments of Michel and Hans-Jürgen significantly strengthen our Board with proven leaders in drug development, regulatory strategy, capital markets, strategic transactions and M&A. This Board has been assembled to support MRM Health as we advance MH002 through Phase 2b, prepare for late-stage development and position the Company for its next key milestones. Backed by our CORAL® platform and the positive Phase 2a data generated to date, we are convinced MH002 can become a cornerstone of next-generation microbiome therapeutics,” said Dr. Sam Possemiers, CEO of MRM Health.
